Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

Overview

This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination series in children below 18 years of age.

Full Title of Study: “A Randomized, Controlled, Dose-finding, Observer-blind, Phase 2/3 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccines (SCB-2019 Vaccine) in Children <18 Years of Age”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2024

Interventions

  • Biological: Candidate vaccine, SCB-2019
    • a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Arms, Groups and Cohorts

  • Experimental: SCB-2019/SCB-2019/placebo, 12 to < 18 yrs
    • Day 1 and 22: SCB-2019, Day 43: placebo
  • Experimental: Placebo/SCB-2019/SCB-2019, 12 to < 18 years
    • Day 1: placebo, Day 22 and 43: SCB-2019
  • Experimental: SCB-2019/placebo/SCB-2019, 12 to < 18 years
    • Day 1 and 43: SCB-2019, Day 22: placebo
  • Experimental: Low dose SCB-2019, 5 to < 12 years
    • Day 1 and 22: SCB-2019
  • Experimental: Mid dose SCB-2019, 5 to < 12 years
    • Day 1 and 22: SCB-2019
  • Experimental: High dose SCB-2019, 5 to < 12 years
    • Day 1 and 22: SCB-2019
  • Experimental: SCB-2019/SCB-2019/placebo, 5 to < 12 yrs
    • Day 1 and 22: SCB-2019, Day 43: placebo
  • Experimental: Placebo/SCB-2019/SCB-2019, 5 to < 12 years
    • Day 1: placebo, Day 22 and 43: SCB-2019
  • Experimental: SCB-2019/placebo/SCB-2019, 5 to < 12 years
    • Day 1 and 43: SCB-2019, Day 22: placebo
  • Experimental: Low dose SCB-2019, 2 to < 5 years
    • Day 1 and 22: SCB-2019
  • Experimental: Mid dose SCB-2019, 2 to < 5 years
    • Day 1 and 22: SCB-2019
  • Experimental: High dose SCB-2019, 2 to < 5 years
    • Day 1 and 22: SCB-2019
  • Experimental: SCB-2019/SCB-2019/placebo, 2 to < 5 yrs
    • Day 1 and 22: SCB-2019, Day 43: placebo
  • Experimental: Placebo/SCB-2019/SCB-2019, 2 to < 5 years
    • Day 1: placebo, Day 22 and 43: SCB-2019
  • Experimental: SCB-2019/placebo/SCB-2019, 2 to < 5 years
    • Day 1 and 43: SCB-2019, Day 22: placebo
  • Experimental: Low dose SCB-2019, birth to < 2 years
    • Day 1 and 22: SCB-2019
  • Experimental: Mid dose SCB-2019, birth to < 2 years
    • Day 1 and 22: SCB-2019
  • Experimental: High dose SCB-2019, birth to < 2 years
    • Day 1 and 22: SCB-2019
  • Experimental: SCB-2019/SCB-2019/placebo, birth to < 2 yrs
    • Day 1 and 22: SCB-2019, Day 43: placebo
  • Experimental: Placebo/SCB-2019/SCB-2019, birth to < 2 years
    • Day 1: placebo, Day 22 and 43: SCB-2019
  • Experimental: SCB-2019/placebo/SCB-2019, birth to < 2 years
    • Day 1 and 43: SCB-2019, Day 22: placebo

Clinical Trial Outcome Measures

Primary Measures

  • Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety
    • Time Frame: 7 days after dose 1 (Day 1-7)
    • Proportion of subjects with solicited local and systemic adverse events
  • Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety
    • Time Frame: 7 days after dose 2 (Day 22-28)
    • Proportion of subjects with solicited local and systemic adverse events
  • Phase 2, select optimal dose level of SCB-2019 vaccine in phase 2 by age cohort (5-11 years, 2-4 years, and < 2 years), based on immunogenicity
    • Time Frame: Day 36
    • Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibody (nAb)
  • Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years)
    • Time Frame: 21/15 days after second SCB-2019 dose
    • GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to 12 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study
  • Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years)
    • Time Frame: 21/15 days after second SCB-2019 dose
    • GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 2 to 5 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study
  • Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years)
    • Time Frame: 21/15 days after second SCB-2019 dose
    • GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants birth to 2 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study

Secondary Measures

  • Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years)
    • Time Frame: 21/15 days after second SCB-2019 dose
    • Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to < 12 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study
  • Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years)
    • Time Frame: 21/15 days after second SCB-2019 dose
    • Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 2 to < 5 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study
  • Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years)
    • Time Frame: 21/15 days after second SCB-2019 dose
    • Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants birth to < 2 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study
  • In phase 2 and 3, GMT of SARS-CoV-2 nAb
    • Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, proportion of participants achieving seroconversion for SARS-CoV-2 nAb
    • Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, GMFR in SARS-CoV-2 nAb
    • Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, proportion of participants with SARS-CoV-2 nAb above a certain threshold
    • Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, GMT of SCB-2019 Binding Antibody
    • Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, proportion of participants achieving seroconversion for SCB-2019 binding antibody
    • Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, GMFR of SCB-2019 binding antibody
    • Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
  • In phase 2 and 3, proportion of participants with SCB-2019 binding antibody above a certain threshold
    • Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
  • In phase 3, reactogenicity of the vaccine as indicated by the occurrence of solicited local and systemic reactions
    • Time Frame: 7 days after dose 1 (Day 1-7), dose 2 (Day 22-Day 28) and Dose 3 (Day 43-49)
    • In phase 3, proportion of participants with local and systemic AEs
  • Phase 2 and 3, safety of the vaccine in terms of occurrence of unsolicited adverse events
    • Time Frame: Up to 21 days after the last vaccination
    • Proportion of subjects with unsolicited adverse events
  • Phase 2 and 3, safety of the vaccine in terms of occurrence of MAAEs, SAEs, adverse events leading to discontinuation from study, and AESIs.
    • Time Frame: During the entire study period
    • Proportion of participants with any adverse events in this category.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female <18 years of age. Participants will be stratified into different age cohorts (≥12 to < 18 years, ≥5 to < 12 years, ≥2 to < 5 years, and < 2 years of age) based on the age on the day of inclusion. – Individuals and their legally authorized representative (LAR) are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests and other study procedures. – Individuals are willing and able to give an assent (if applicable) and their LARs are willing and able to give informed consent on their behalf, prior to screening – Healthy participants (phase 2 and phase 3) or participants with pre-existing medical conditions who are in a stable medical condition (phase 2) – For infants (<1-year-old) – born at full term (gestational age ≥37 weeks) and with a normal birth weight (≥2500 grams). – Female participants of childbearing potential may be enrolled in the study, if the participant has practiced highly effective contraception for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination and has agreed to continue adequate contraception for 3 months after the last vaccination Exclusion Criteria:

  • Individuals with fever >38.0°C [≥ 100.4°F] (irrespective of method used), or any acute illness at baseline (Day 1) or within 3 days prior to randomization. – Individuals with laboratory-confirmed SARS-CoV-2 infection [as defined by Rapid COVID Antigen Test or an equivalent at Day 1] or with history of laboratory-confirmed/medically-diagnosed COVID-19 (for phase 2 participants only). – Individuals who have received an investigational or licensed COVID-19 vaccine prior to Day 1, or plan to receive an investigational or licensed COVID-19 vaccine during the study period. – Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease [e.g., malignancy, human immunodeficiency virus (HIV) infection] or immunosuppressive/cytotoxic therapy (e.g., systemic corticosteroids, medications used for cancer chemotherapy, organ transplantation or to treat autoimmune disorders) within 3 months prior to Day 1. Inhaled, intranasal, topical steroids as well as a single dose of systemic steroids, are allowed. – Individuals with any progressive or severe neurologic disorder, seizure disorder (including febrile seizures) or history of Guillain-Barré syndrome. – Individuals who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or during the study period. – Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction – Individuals who have received any other investigational product within 30 days prior to Day 1 or intend to participate in another clinical study at any time during the conduct of this study. – Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 28 days after the second (phase 2) or third (phase 3) vaccination. – Individuals with known bleeding disorder that would, in the opinion of the investigator, contraindicate intramuscular injection – Administration of intravenous immunoglobulins and/or any blood products within 3 months prior to enrollment or planned administration during the study period – Individuals with any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Clover Biopharmaceuticals AUS Pty Ltd
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Margaret Khin, MD, Margaret.Khin@cloverbiopharma.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.